Sodium Zirconium Cyclosilicate

This study aimed to detect and contrast the adverse drug event (ADE) signals associated with sodium zirconate cyclosilicate (SZC) and Patiromer by leveraging the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), thereby informing safer clinical decision-making and optimizing therapeutic selection in hyperkalemic patients. We utilized multiple signal detection algorithms, including the reporting odds ratio (ROR), the UK Medicines and Healthcare products Regulatory Agency method, Bayesian confidence propagation neural networks, and the multi-item gamma Poisson shrinker, to extract adverse reaction signals for SZC (from Q2 2018 to Q3 2024) and Patiromer (from Q4 2015 to Q3 2024) from the FAERS database. Our analysis encompassed 8586,052 reports for SZC and 11,937,823 for Patiromer, with 1559 and 12,715 reports, respectively, flagged as primary suspect drugs. The most reports originated from the United States (SZC: 74.21%, Patiromer: 96.02%). The primary reporters were consumers for SZC (34.38%), physicians (31.50%), and consumers for Patiromer (68.16%). Both medications were predominantly prescribed for hyperkalemia management (SZC: 74.93%, Patiromer: 57.84%). We detected 51 significant signals for SZC and 122 for Patiromer. Key signals for SZC involved mortality, increased blood potassium, constipation, hypokalemia, and edema. For Patiromer, prominent signals comprised constipation, death, product leakage issues, and diarrhea. SZC primarily influenced systemic disorders and gastrointestinal complications, whereas Patiromer was associated with gastrointestinal conditions, systemic effects, and reactions at the administration site. Healthcare providers should consider adverse drug events not documented in the prescribing information for SZC (such as hypernatremia, mortality, and congestive heart failure) and Patiromer (such as Individuals undergoing dialysis or using pacemakers might encounter complications like arteriovenous fistula disorders and pacemaker modifications). Positive signals for Patiromer also indicate concerns regarding product solubility, color, taste, and texture, potentially impacting patient compliance. Due to the high frequency of death reports associated with both drugs (SZC: 573, Patiromer: 1656), clinicians should exercise heightened vigilance.

Hyperkalemia is a potentially life-threatening electrolyte imbalance that contributes to increased morbidity and mortality in patients with heart failure (HF) and chronic kidney disease (CKD). Novel potassium binders (NPBs) have been shown to prevent hyperkalemia; however, their efficacy and safety have not been fully established.

We searched various electronic databases, including MEDLINE (via PubMed), Embase, the Cochrane Library, and ClinicalTrials.gov, to retrieve randomized controlled trials comparing NPB to placebo in patients with chronic hyperkalemia due to HF or CKD.

Our meta-analysis, including 12 studies involving 2517 patients, showed that NPBs, including patiromer and sodium zirconium cyclosilicate, were associated with significant mineralocorticoid receptor antagonist (MRA) optimization (relative risk [RR]: 1.28; 95% confidence interval [CI]: 1.14-1.43) as compared to placebo. The results were consistent for subgroups of sodium zirconium cyclosilicate, patiromer, CKD, and HF. NPBs also significantly reduced the incidence of hyperkalemia (RR: 0.37; 95% CI: 0.22-0.6). Additionally, NPBs reduced the mean serum potassium level from baseline as compared to placebo (mean difference: -0.46; 95% CI: -0.77 to -0.15) and MRA optimization at less than the target dose (RR: 0.62; 95% CI: 0.42-0.85). The risk of adverse events, serious adverse events, and all-cause mortality remained comparable between the two groups.

This meta-analysis highlights the potential of NPBs to facilitate MRA optimization, reduce hyperkalemic episodes, and maintain serum potassium levels in patients with hyperkalemia, without a corresponding increase in adverse events. However, further research through large-scale studies is needed to confirm the sustained clinical benefits of NPBs, establish standardized treatment protocols, and evaluate their effectiveness across diverse patient populations with CKD and HF.